Iberdomide Plus Daratumumab and Dexamethasone Doubles MRD-Negative Complete Response Rate in Relapsed/Refractory Multiple Myeloma

Results from the Phase 3 EXCALIBER-RRMM trial indicate that a regimen of iberdomide (Zenbexus) combined with daratumumab (Darzalex) and dexamethasone (IDd) more than doubled the rate of minimal residual disease (MRD)-negative complete response compared to standard therapy (daratumumab, bortezomib, and dexamethasone) in patients with relapsed or refractory multiple myeloma. These findings were presented at the International Myeloma Society (IMS) 2026 Annual Meeting and published in The Lancet Oncology.

Context

Multiple myeloma is a type of blood cancer characterized by the proliferation of abnormal plasma cells. Patients often experience relapse after initial treatment, making effective therapies crucial. The standard treatment has included combinations of daratumumab, bortezomib, and dexamethasone, but newer options are needed to enhance response rates and overall survival.

Why it matters

The findings from the EXCALIBER-RRMM trial represent a significant advancement in the treatment of relapsed or refractory multiple myeloma. By demonstrating that iberdomide combined with daratumumab and dexamethasone can more than double the MRD-negative complete response rate, this regimen may improve patient outcomes. This could lead to changes in clinical practice and treatment guidelines for multiple myeloma.

Implications

If adopted widely, the new treatment regimen could lead to better management of multiple myeloma, potentially reducing the burden of disease on patients. This may also impact healthcare costs and resource allocation in oncology. Patients with relapsed or refractory multiple myeloma could experience improved quality of life and survival rates.

What to watch

Following the presentation of these results, healthcare providers may begin to evaluate the integration of iberdomide into treatment regimens. Regulatory approvals and guidelines may be updated based on the trial's findings. Additionally, further studies may be initiated to explore the long-term effects and safety of this combination therapy.